DYNE THERAPEUTICS INC's ticker is DYN and the CUSIP is 26818M108. A total of 70 filers reported holding DYNE THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2023 | $27,594,667 | +38.7% | 2,074,787 | -6.5% | 32.85% | +6.7% |
| Q3 2023 | $19,891,505 | -20.4% | 2,220,034 | 0.0% | 30.79% | -5.6% |
| Q2 2023 | $24,975,383 | -2.3% | 2,220,034 | 0.0% | 32.61% | -6.8% |
| Q1 2023 | $25,574,792 | -0.6% | 2,220,034 | 0.0% | 34.99% | +1.2% |
| Q4 2022 | $25,730,194 | -8.7% | 2,220,034 | 0.0% | 34.58% | +36.6% |
| Q3 2022 | $28,194,000 | +38.6% | 2,220,034 | -25.0% | 25.30% | +47.3% |
| Q2 2022 | $20,335,000 | -28.7% | 2,960,046 | 0.0% | 17.18% | +3.5% |
| Q1 2022 | $28,535,000 | -18.9% | 2,960,046 | 0.0% | 16.60% | +26.1% |
| Q4 2021 | $35,195,000 | -26.8% | 2,960,046 | 0.0% | 13.16% | -4.4% |
| Q3 2021 | $48,071,000 | -22.8% | 2,960,046 | 0.0% | 13.77% | -11.8% |
| Q2 2021 | $62,280,000 | +35.5% | 2,960,046 | 0.0% | 15.62% | +34.5% |
| Q1 2021 | $45,970,000 | -26.0% | 2,960,046 | 0.0% | 11.61% | -9.0% |
| Q4 2020 | $62,161,000 | +4.0% | 2,960,046 | 0.0% | 12.76% | -65.9% |
| Q3 2020 | $59,764,000 | – | 2,960,046 | – | 37.43% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vida Ventures Advisors, LLC | 2,960,046 | $35,195,000 | 13.16% |
| MPM ASSET MANAGEMENT LLC | 4,951,303 | $58,871,000 | 12.72% |
| Atlas Venture Life Science Advisors, LLC | 8,934,902 | $106,236,000 | 9.76% |
| Logos Global Management LP | 3,234,392 | $38,457,000 | 3.97% |
| GREAT POINT PARTNERS LLC | 845,000 | $10,047,000 | 2.23% |
| Deep Track Capital, LP | 2,292,250 | $27,255,000 | 1.92% |
| Octagon Capital Advisors LP | 583,649 | $6,940,000 | 1.35% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 476,000 | $5,641,000 | 1.26% |
| COMMODORE CAPITAL LP | 305,125 | $3,628,000 | 0.84% |
| RA Capital Management | 2,805,045 | $33,352,000 | 0.59% |